A series of site-directed mutations in P1, E1 or both sites within the
hlh-1 enhancer
enh1::
myo-2::gfp::lacZ transgene demonstrate that the P1 and E1 sites are both necessary and sufficient for robust
enh-1 responsiveness in vivo to PAL-1 and HLH-1, respectively.